Linaprazan
Based on 1 Customer Validation
Linaprazan (AZD0865) can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding, (IC50: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) can be used for research on reflux esophagitis with oral activity.
For research use only. We do not sell to patients.
- Purity: 98.09%
- CAS No.: 248919-64-4
- Formula: C21H26N4O2
- Molecular Weight:366.46
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Biological Activity
Linaprazan (AZD0865) inhibits acid formation in rabbit gastric glands stimulated by histamine or dibutyryl cAMP (IC50 values of 0.28 and 0.26 μM, respectively)[1].
Linaprazan (AZD0865) mesylate (3 μM, pH 7.4) inhibits H+, K+-ATPase activity by 88.1%[1].
Linaprazan (AZD0865) mesylate inhibits H+, K+-ATPase activity in a K+-competitive manner (Ki=46 nM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Pharmacokinetic analysis of 2.4 mg/kg Linaprazan after single oral administration in SD rats[3]
| Sex | t1/2 (h) | Tmax (h) | Cmax (ng eq./g) | AUC0-t (ng·h eq./g) | AUC0-∞ (ng·h eq./g) | AUC% (%) |
| Male | 5.08 | 4.67 | 455 | 5960 | 6200 | 4.12 |
| Femal | 4.64 | 4.00 | 1270 | 13900 | 14300 | 3.10 |